Kim E. Lazarus Wolensky

Bradley Pharmaceuticals, Inc. is a specialty pharmaceutical company, engages in the acquisition, development and marketing of prescription and products to physician specialties in the United States and international markets. The company has two divisions: Doak Dermatologics and Kenwood Therapeutics. The Doak Dermatologics division promotes branded dermatologic and podiatric products including ADOXA, KERALAC, SOLARAZE, ZODERM, LIDAMANTLE, ROSULA, SELSEB and ZONALON to dermatologists and podiatrists. The Kenwood Therapeutics division offers branded gastrointestinal products including ANAMANTLE HC, PAMINE and PAMINE FORTE to gastroenterologists, colon and rectal surgeons. It also markets nutritional supplements and respiratory products including FLORA-Q. The company’s products are used in the treatment of acne, mild to severe dry skin and nail disorders, actinic keratoses, precancerous skin lesions, topical anesthetic and anti-inflammatory diseases, dandruff, hemorrhoids and anal fissures. It markets and sells it's products through sales personnel and wholesalers. The company was founded by Daniel Glassman in 1985 and is headquartered in Fairfield, NJ.